{"entity":{"id":"sengine","kind":"company","name":"SEngine Precision Medicine","aka":[],"tldr":"Runs the PARIS test: a patient's tumour grown as organoids and screened against 240+ drugs to find options sequencing cannot see.","summary":"SEngine Precision Medicine, based in Seattle, runs the PARIS test, in which a patient's tumour is grown as organoids and screened against more than 240 drugs to find options that sequencing cannot see. It is CLIA-certified in all fifty states and approved by New York's CLEP, PARIS uses three-dimensional organoids from any solid tumour to rank drug sensitivity, it collaborates with Dana-Farber and Gustave Roussy, and it has raised about 19 million dollars through its Series A. OnCo links it to functional ex vivo drug testing and patient-derived organoids, to the bottleneck of preclinical models that do not predict people, and to the idea of holding organoid tests to the standard of a diagnostic. Whether organoid drug sensitivity predicts patient response well enough to guide therapy is the open question. The organoid technology page carries the evidence.","asOf":"2026-09-04","links":[{"label":"NY CLEP approval","url":"https://www.biospace.com/sengine-precision-medicine-receives-new-york-state-clep-approval-for-paris-test"}],"tags":[],"related":[],"cancers":[],"sections":["diagnostics","drug-discovery"],"technologies":["functional-drug-testing","organoids"],"targets":[],"drugs":[],"companies":[],"institutions":["dana-farber","gustave-roussy"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Seattle, WA","country":"US","companyType":"diagnostics","website":"https://senginemedicine.com","investors":[],"funding":[]},"route":"/companies/sengine/","neighbours":{"section":[{"id":"diagnostics","kind":"section","name":"Diagnostics & Biomarkers","route":"/fronts/diagnostics/"},{"id":"drug-discovery","kind":"section","name":"Drug Discovery Platforms","route":"/fronts/drug-discovery/"}],"technology":[{"id":"functional-drug-testing","kind":"technology","name":"Functional (ex vivo) drug testing","route":"/technologies/functional-drug-testing/"},{"id":"organoid-guided-therapy-scale","kind":"technology","name":"Organoid-guided therapy at scale","route":"/technologies/organoid-guided-therapy-scale/"},{"id":"organoids","kind":"technology","name":"Patient-derived organoids","route":"/technologies/organoids/"}],"institution":[{"id":"dana-farber","kind":"institution","name":"Dana-Farber Brigham Cancer Center","route":"/institutions/dana-farber/"},{"id":"gustave-roussy","kind":"institution","name":"Gustave Roussy","route":"/institutions/gustave-roussy/"}],"bottleneck":[{"id":"b-preclinical-models","kind":"bottleneck","name":"Lab models that fail to predict what happens in patients","route":"/bottlenecks/b-preclinical-models/"}],"idea":[{"id":"idea-tr2-organoid-coclinical-arms","kind":"idea","name":"Grow each trial patient's tumour as organoids to decide which platform arm opens next","route":"/ideas/idea-tr2-organoid-coclinical-arms/"},{"id":"idea-bio1-organoid-assay-clinical-validation","kind":"idea","name":"Hold organoid drug tests to the same standard as a diagnostic test","route":"/ideas/idea-bio1-organoid-assay-clinical-validation/"},{"id":"idea-bio2-functional-precision-rare","kind":"idea","name":"Test drugs on the patient's own cancer cells when there is no trial to join","route":"/ideas/idea-bio2-functional-precision-rare/"}],"roadmap":[{"id":"drug-discovery-roadmap","kind":"roadmap","name":"Drug discovery roadmap: screening in mice → maps of dependency → designing in silico","route":"/roadmaps/drug-discovery-roadmap/"}]}}